Showing results (41-50 of 71) with videos related to
Sort By:
Pageof 8
Expert Opinion on Biological Therapy|April 11, 2023
Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD)Bernd Bokemeyer, Tibor Hlavaty, Matthieu Allez, et al.Gastroenterology|June 25, 2011
FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel diseaseRayko Evstatiev, Philippe Marteau, Tariq Iqbal, et al.Journal of Crohn'S & Colitis|May 14, 2013
Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II)Laurence Egan, Renata D'Inca, Tine Jess, et al.World Journal of Gastroenterology|September 26, 2014
Parameters of a severe disease course in ulcerative colitisAndreas Stallmach, Luisa Nickel, Thomas Lehmann, et al.Journal of Clinical Medicine|January 8, 2025
Women with IBD Show Higher Psychophysiological Burden in Comparison to Men with IBDFranziska Schulz, Ann Christina Foldenauer, Lara Weidmann, et al.Journal of Crohn'S & Colitis|September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient QuestionnaireEman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.International Journal of Colorectal Disease|March 20, 2023
Burden of disease among patients with prevalent Crohn's disease: results from a large German sickness fundEvi Zhuleku, Beatriz Antolin-Fontes, Andras Borsi, et al.Alimentary Pharmacology & Therapeutics|March 2, 2024
Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO-ASSIST study)Bernd Bokemeyer, Sandra Plachta-Danielzik, Isa Maria Steiner, et al.Alimentary Pharmacology & Therapeutics|June 16, 2023
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -studyBernd Bokemeyer, Sandra Plachta-Danielzik, Romina di Giuseppe, et al.The American Journal of Gastroenterology|April 26, 2006
Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's diseaseKlaus R Herrlinger, Thomas Witthoeft, Andreas Raedler, et al.Pageof 8